Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sunshine Acquires Remaining Rights to Adva-27a | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sunshine Acquires Remaining Rights to Adva-27a

Anticancer compound shows potential in pancreatic cancer, breast cancer, small-cell lung cancer and uterine sarcoma

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sunshine Biopharma has acquired all of the remaining rights to its anticancer compound Adva-27a for $12.8 million, which will be paid with quarterly payments through December 2020. The Patent Purchase Agreement provides direct ownership of all issued and pending Adva-27a related patents and intellectual property worldwide. Sunshine previously had ownership of only the U.S. patent.
 
Adva-27a is a Topoisomerase II inhibitor, small molecule that has recently been shown to be effective at killing pancreatic cancer cells, multidrug resistant breast cancer cells, small-cell lung cancer cells and uterine sarcoma cells. Adva-27a is currently in the IND-Enabling stage of development, with plans for Phase I trials in pancreatic cancer and multidrug resistant breast cancer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics